Tandem Isotope Therapy with <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA-617 in a Murine Model of Prostate Cancer.

Authors:
Meyer C; Stuparu A; Lueckerath K; Calais J; Czernin J and 2 more

Journal:
J Nucl Med

Publication Year: 2023

DOI:
10.2967/jnumed.123.265433

PMCID:
PMC10626377

PMID:
37797974

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Nucl Med

Abbreviation: J Nucl Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nuclear Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
Benabdallah N; Lu P; Abou DS and 16 more (2024) - Transparency Score: 3/6
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatoce…
Garin E; Tselikas L; Guiu B and 16 more (2024) - Transparency Score: 3/6
MRI or <sup>18</sup>F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology, and Alzh…
Doering E; Antonopoulos G; Hoenig M and 9 more (2024) - Transparency Score: 4/6
Phase II Trial Assessing the Repeatability and Tumor Uptake of [<sup>68</sup>Ga]Ga-HER2 Single-Doma…
Gondry O; Caveliers V; Xavier C and 21 more (2024) - Transparency Score: 3/6
<sup>18</sup>F-FAPI-04 Outperforms <sup>18</sup>F-FDG PET/CT in Clinical Assessments of Patients wi…
Li X; Lu N; Lin L and 9 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"DISCLOSURE Katharina Lueckerath reports paid consulting activities for Sofie Biosciences/iTheranostics and funding from AMGEN outside the submitted work. Jeremie Calais reports prior consulting activities for Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, EXINI, IBA RadioPharma, Janssen Pharmaceuticals, Lantheus, POINT Biopharma, Progenics, Radiomedix, and Telix Pharmaceuticals. No other potential conflict of interest relevant to this article was reported."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025